Annual report pursuant to Section 13 and 15(d)

Intangible Assets

Intangible Assets

12 Months Ended

Mar. 31, 2014

Note 3. Intangible Assets

With the acquisition of CollabRx, as of March 31, 2014, the Company’s intangible assets net value was $1,281. The Company does not amortize the trade name as it has an indefinite life subject to annual impairment tests. The net book value of Goodwill was $603.

As of March 31, 2014, intangible assets, net, not including goodwill, consisted of the following:

	Gross		Accumulated Amortization			Net
Developed Technology	$	719	$	(128	)	$	591
Customer Relationships		433		(152	)		281
Trade Name		346		-			346
Non Compete Agreement		151		(88	)		63
Total	$	1,649	$	(368	)	$	1,281

Amortization expense was $209 and $160 in fiscal 2014 and 2013, respectively.

As of March 31, 2013, intangible assets, net not including goodwill, consisted of the following:

	Gross		Accumulated Amortization			Net
Developed Technology	$	719	$	(56	)	$	663
Customer Relationships		433		(65	)		368
Trade Name		346		-			346
Non Compete Agreement		151		(38	)		113
Total	$	1,649	$	(159	)	$	1,490

Future estimated amortization expense is as follows:

Year Ending March 31,	Estimated Amortization Expense
2015	$	209
2016		171
2017		159
2018		94
2019		72
Thereafter		230
	$	935

The Company sold all remaining intangibles, except the NLD related patents, to SPTS on February 9, 2011. The Company retained the internally developed NLD patents and has sold all of these patents as of March 31, 2014.

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References + Details